Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30327328 | 0.84 | ADRA2C (0.64) | L3MBTL1LMNASMN1; SMN2ATMTDP1 | |
| SCHEMBL2342698 | 0.84 | ADRA2C (0.64) | L3MBTL1LMNASMN1; SMN2ATMTDP1 | |
| SCHEMBL11325646 | 0.84 | MAPT (0.55) | LMNANPSR1ATMCYP1A2CYP3A4 | |
| SCHEMBL10416922 | 0.84 | NPSR1 (0.50) | L3MBTL1LMNASMN1; SMN2NPSR1ATM | |
| SCHEMBL17086922 | 0.83 | MEN1 (0.45) | L3MBTL1LMNASMN1; SMN2NPSR1ATM | |
| SCHEMBL8787198 | 0.82 | L3MBTL1 (0.64) | L3MBTL1LMNASMN1; SMN2NPSR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL11330417 | 0.81 | NPSR1 (0.48) | L3MBTL1LMNASMN1; SMN2NPSR1ATM | |
| SCHEMBL31078153 | 0.80 | ALDH1A1 (0.59) | L3MBTL1CYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL7646955 | 0.79 | BRD4 (0.74) | LMNAGAAMEN1KMT2A | |
| SCHEMBL8977174 | 0.78 | MAPT (0.61) | LMNASMN1; SMN2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841320-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY | 2014-09-23 | — | — | US | disclosed |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | VANDERBILT UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-8372868-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372868-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2013-02-12 | — | — | US | disclosed |
| US-8188116-B2 | Ligand/drug conjugates; near infrared radiation imaging; peripheral benzodiazepine receptor imaging; drug delivery; drug targets; cancer, metastasis | VANDERBILT UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188116-B2 | Ligand/drug conjugates; near infrared radiation imaging; peripheral benzodiazepine receptor imaging; drug delivery; drug targets; cancer, metastasis | VANDERBILT UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188116-B2 | Ligand/drug conjugates; near infrared radiation imaging; peripheral benzodiazepine receptor imaging; drug delivery; drug targets; cancer, metastasis | VANDERBILT UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110097269-A1 | PHENYLOXYANILINE DERIVATIVES | LEHMANN LUTZ | 2011-04-28 | — | — | US | disclosed |
| US-20110097269-A1 | PHENYLOXYANILINE DERIVATIVES | LEHMANN LUTZ | 2011-04-28 | — | — | US | disclosed |
| US-20110097269-A1 | PHENYLOXYANILINE DERIVATIVES | LEHMANN LUTZ | 2011-04-28 | — | — | US | disclosed |
| EP-2064176-A1 | PHENYLOXYANILINE DERIVATIVES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008143706-A2 | DAA PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR CANCER IMAGING AND TREATMENT | VANDERBILT UNIVERSITY (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080177108-A1 | Phenyloxyaniline derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080177108-A1 | Phenyloxyaniline derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080177108-A1 | Phenyloxyaniline derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008028533-A1 | PHENYLOXYANILINE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008028533-A1 | PHENYLOXYANILINE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-02-07 | — | — | US | disclosed |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-02-07 | — | — | US | disclosed |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | TSPO, MKI67, CNR1 | L3MBTL1 2590/4885LMNA 3556/4885SMN1; SMN2 1978/4885 |
| US-20110097269-A1 | PHENYLOXYANILINE DERIVATIVES | PNMT, PAH, NAT1 | L3MBTL1 3352/4885LMNA 3930/4885SMN1; SMN2 3923/4885 |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | TSPO, MKI67, GABRA4 | L3MBTL1 2678/4885LMNA 3132/4885SMN1; SMN2 1917/4885 |
| US-20080177108-A1 | Phenyloxyaniline derivatives | PNMT, PAH, NAT1 | L3MBTL1 3352/4885LMNA 3930/4885SMN1; SMN2 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.